Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.
Boundless Bio has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in May 2023.
Boundless Bio's investors include RA Capital Management, ARCH Venture Partners, Wellington Management, Redmile Group, Vertex Ventures.
Boundless Bio is headquartered in La Jolla, United States.
Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.
Boundless Bio is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Boundless Bio — Funding & Investors." VCBacked, May 16, 2023, https://www.vcbacked.co/company/boundless-bio. Accessed July 19, 2026.
VCBacked. (2023). Boundless Bio — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/boundless-bio
{{cite web |title=Boundless Bio — Funding & Investors |url=https://www.vcbacked.co/company/boundless-bio |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated